Shirley et al, Neuropsychopharmacology (2003) 28, 961–966
Olanzapine, an atypical antipsychotic agent used in the treatment of schizophrenia, is metabolized to 10- and 4'-N-glucuronide, 4'-N-desmethylolanzapine via CYP1A2. Here is report demonstrating the relationship between (orally administered) olanzapine clearance/F and the metabolic ratio (PMR = 17X/137X) measured using caffeine.
Laika et al, The Pharmacogenomics Journal (2010) 10, 20–29
Notwithstanding the lack of predictive value of CYP1A2 genetics on CYP1A2 activity, here is a study looking at the effect of the presence of CYP1A2*1F allele on olanzapine steady state plasma concentrations, in the presence/absence of inducers such as smoking and carbamazepine.
While both inducers and *1F/*1F genotype showed significant effects on average olanzapine concentrations, the scatter within each group remains very large, and is clearly not explained by either effects.
Posts
Thanks for shearing about this I thinks its very hopeful post and very important post for us.Thanks for your great and helpful presentation I like your good service.I always appreciate your post.
ReplyDeletepharmacogenetic tests